PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes News - 10th September 2024
PhoreMost Achieves Second Milestone in Target Discovery Alliance with Boehringer Ingelheim News - 3rd June 2024
PhoreMost introduces GlueSEEKER™ platform for discovery of molecular glue degraders News - 21st May 2024